Safety study of immune globulin for primary immunodeficiency
Part of Genetic & congenital, Immune system & allergy clinical trials.
This study is a safety check for people with primary immunodeficiency who are already using a specific immune globulin treatment given under the skin. It looks at medical records to see if any side effects occurred.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a primary immunodeficiency (a condition that weakens your immune system).
- You are already enrolled in a special registry for people with primary immunodeficiency.
- Your medical records show that you have used a specific immune globulin treatment (given under the skin).
- Your doctors have recorded whether you had any side effects from treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new intravenous immunoglobulin (IVIG) treatment for patients with primary immunodeficiency diseases, such as common variable immune deficiency (CVID) or X-linked agammaglobulinemia (XLA). It aims to see if this medicine is safe and works well to prevent infections.
This study looks at children who may have inborn errors of immunity, which are problems with the immune system that make it hard to fight infections. The trial tracks children with certain warning signs to learn more about these conditions.
This study examines how well immunoglobulin replacement therapy works in people with primary antibody immunodeficiency—a rare condition where the body cannot make enough antibodies to fight infections. Researchers will also study immune system changes to understand treatment response better.
This trial tests a new medicine (BP-SCIG 20%) given under the skin to help children and adults with primary immunodeficiency who have trouble making antibodies. It aims to see if the medicine is safe and works well to prevent infections.
This trial tests an investigational intravenous immunoglobulin (IVIG) called Boya for people with primary immune deficiencies like CVID or XLA. It aims to see if the treatment is safe and works well to prevent infections.
This study collects blood (and sometimes related samples) to learn how genes and the immune system work in people with primary immunodeficiency (PID) or in family members who may not have it. The goal is to improve understanding of rare immune conditions and help guide future care.
Hear when a new Primary Immunodeficiency Diseases (PID) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.